Best CGM for Medicare Patients in 2026: 4 Approved Devices

Medicare Part B covers continuous glucose monitors for patients with diabetes who use insulin and meet specific eligibility criteria. As of 2026, 4 CGM devices are Medicare-approved: the Dexcom G7, Dexcom G7 15-Day, FreeStyle Libre 3 Plus, and Medtronic Guardian 4. Medicare coverage typically results in patient copays of $0 to $50 per month for CGM sensors and supplies, making continuous glucose monitoring accessible for the 12+ million Medicare beneficiaries living with diabetes.

To qualify for Medicare CGM coverage, patients must have a diabetes diagnosis (type 1 or insulin-treated type 2), use insulin, check blood glucose at least 4 times per day (or have documentation of CGM medical necessity), and have an order from their treating physician. The coverage falls under Medicare Part B durable medical equipment (DME), and patients receive sensors and supplies through Medicare-contracted DME suppliers rather than retail pharmacies. Medicare does not cover over-the-counter CGMs (Dexcom Stelo, Abbott Lingo, Libre Rio) because they are classified as wellness devices rather than therapeutic medical devices.

The FreeStyle Libre 3 Plus is the best CGM for most Medicare patients because it offers the highest accuracy (7.9% MARD), lowest copay ($15 to $30/month), and 15-day wear time. The Dexcom G7 15-Day is the better choice for Medicare patients who use an insulin pump (Omnipod 5 or Tandem) because it provides closed-loop integration that the Libre 3 Plus does not support.